First Trust Advisors LP and Truist Securities have increased their stock positions in Genmab A/S (NASDAQ:GMAB), in contrast to Franklin Resources Inc., and Capital International Investors who reduced their stakes. Genmab A/S's stock slumped following a $1.8 billion takeover of ProfoundBio. However, the company implemented a major share buy-back initiative, indicating confidence in its future financial performance. Genmab A/S has seen increased short interest, indicating potential hostility from investors. Meanwhile, a number of other investment firms, including, Campbell & CO Investment Adviser LLC, have also taken million-dollar positions in Genmab A/S. The share price for Genmab A/S was cut down to below the 200-day moving average, but it was given a 'Buy' rating by HC Wainwright. Recently, the company beat EPS and revenue projections for Q1 2024, and experienced an 82% return in the last five years. However, after heavy losses in value, institutional owners might be considering drastic measures. Genmab A/S's stock has been given an average rating of 'Hold' by analysts and had a setback with a recent arbitrage loss. Despite some controversy, the company continues to invest in oncology with the acquisition of ProfoundBio.
Genmab Stocks News Analytics from Fri, 14 Aug 2015 07:00:00 GMT to Sun, 09 Jun 2024 15:16:57 GMT -
Rating -2
- Innovation 6
- Information 8
- Rumor 4
